Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

1. Guerrero-Zotano, A.L.
2. Stricker, T.P.
3. Formisano, L.
4. Hutchinson, K.E.
5. Stover, D.G.
6. Lee, K.-M.
7. Schwarz, L.J.
8. Giltnane, J.M.
9. Estrada, M.V.
10. Jansen, V.M.
11. Servetto, A.
12. Gavila, J.J.
13. Perez-Fidalgo, A.
14. Lluch, A.
15. Llombart-Cussac, A.
16. Bayar, M.A.
17. Michiels, S.
18. Andre, F.
19. Arnedos, M.
20. Guillem, V.
21. Ruiz-Simon, A.
22. Arteaga, C.L.